Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions

Bibliography

• Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ 2012;344:e3821
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31
   PubMed Web of Science ®Google Scholar
• Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med 2004;164:1275-84
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Bove A, Siso A. Sjogren's syndrome: beyond sicca involvement. In: Khamashta MA, Ramos-Casals M, editors. Autoimmune diseases. Acute and complex situations. Springer-Verlag; London: 2011. p. 45-66
   Google Scholar
• Theander E, Baecklund E. Cancer. In: Ramos-Casals M, Stone JH, Moutsopoulos HM, editors. Sjogren syndrome: diagnosis and therapeutics. Springer; London: 2012. p. 477-92
   Google Scholar
• Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol 2012;8:399-411
   PubMed Web of Science ®Google Scholar
• Coca A, Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol 2012;24:451-6
   PubMed Web of Science ®Google Scholar
• Westhoff G, Dorner T, Zink A. Fatigue and depression predict physician visits and work disability in women with primary Sjogren's syndrome: results from a cohort study. Rheumatology (Oxford) 2012;51:262-9
   PubMed Web of Science ®Google Scholar
• Belenguer R, Ramos-Casals M, Brito-Zeron P, Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2005;23:351-6
   PubMedGoogle Scholar
• Ibn Yacoub Y, Rostom S, Laatiris A, Hajjaj-Hassouni N. Primary Sjogren's syndrome in Moroccan patients: characteristics, fatigue and quality of life. Rheumatol Int 2012;32:2637-43
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010;304:452-60
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Cervera R, Yague J, Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998;28:200-5
   PubMed Web of Science ®Google Scholar
• Broadley KJ, Kelly DR. Muscarinic receptor agonists and antagonists. Molecules 2001;6:142-93
   Web of Science ®Google Scholar
• Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2001;42:925-32
   PubMed Web of Science ®Google Scholar
• Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjogren's syndrome. Clin Immunol 2001;101:249-63
   PubMed Web of Science ®Google Scholar
• Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49:143-55
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999;159:174-81
   PubMed Web of Science ®Google Scholar
• Papas AS, Sherrer YS, Charney M, Successful treatment of dry mouth and dry eye symptoms in Sjogren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol 2004;10(4):169-77
   PubMed Web of Science ®Google Scholar
• Segal M, Fisher A. AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices. Eur J Pharmacol 1992;220:103-6
   Google Scholar
• Fox RI, Petrone D, Condemi J, Randomized, placebo-controlled trial of SNI-2011, a novel M3 muscarinic receptor agonist, for the treatment of Sjogren's syndrome (abstract). Arthritis Rheum 1998;41(Suppl):S288
   Google Scholar
• Ramos-Casals M, Khamashta MA. Connective tissue disease: trial of SLE therapies in real-world settings. Nat Rev Rheumatol 2012;8:128-30
   Google Scholar
• Moutsopoulos HM, Balow JE, Lawley TJ, Immune complex glomerulonephritis in sicca syndrome. Am J Med 1978;64:955-60
   PubMed Web of Science ®Google Scholar
• Fox PC, Datiles M, Atkinson JC, Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 1993;11:149-56
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P, Siso A, High prevalence of serum metabolic alterations in primary Sjogren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007;34:754-61
   Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106:811-16
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8
   PubMed Web of Science ®Google Scholar
• Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718-29
   PubMed Web of Science ®Google Scholar
• Heaton JM. Antimalarials in treatment of Sjogren's syndrome. Br Med J 1959;1:1512-13
   Google Scholar
• Emmungil H, Kalfa M, Zihni FY, Interstitial cystitis: a rare manifestation of primary Sjogren's syndrome, successfully treated with low dose cyclosporine. Rheumatol Int 2012;32:1215-18
   PubMed Web of Science ®Google Scholar
• Shibata S, Ubara Y, Sawa N, Severe interstitial cystitis associated with Sjogren's syndrome. Intern Med 2004;43:248-52
   PubMed Web of Science ®Google Scholar
• Ogasawara H, Sekiya M, Murashima A, Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjogren's syndrome. Clin Rheumatol 1998;17:160-2
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: csA Phase 3 Study Group. Ophthalmology 2000;107:631-9
   PubMed Web of Science ®Google Scholar
• Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005;112:1790-4
   PubMed Web of Science ®Google Scholar
• Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011;127:315-23
   PubMed Web of Science ®Google Scholar
• Rist S, Sellam J, Hachulla E, Club Rhumatismes et Inflammation. Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjogren's syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken) 2011;63:1339-44
   PubMed Web of Science ®Google Scholar
• Brito-Zeron P, Akasbi M, Bosch X, Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2012; [Epub ahead of print]
   Google Scholar
• Unal-Cevik I, Onal MZ, Odabasi Z, Tan E. IVIG- responsive multiple cranial neuropathy: a pharyngo-facial variant of Guillain-Barre syndrome. Acta Neurol Belg 2009;109:317-21
   Google Scholar
• Rajabally YA, Seow H, Abbott RJ. Immunoglobulin-responsive dysautonomia in Sjogren's syndrome. J Neurol 2007;254:674-5
   Google Scholar
• Canhao H, Fonseca JE, Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjogren's syndrome. J Rheumatol 2000;27:1102-3
   PubMed Web of Science ®Google Scholar
• Dupond JL, Gil H, de Wazieres B. Five-year efficacy of intravenous gammaglobulin to treat dysautonomia in Sjogren's syndrome. Am J Med 1999;106:125
   Web of Science ®Google Scholar
• Mochizuki H, Kamakura K, Masaki T, Motor dominant neuropathy in Sjogren's syndrome: report of two cases. Intern Med 2002;41:142-6
   Google Scholar
• Friedman J, Klepfish A, Miller EB, Agranulocytosis in Sjogren's syndrome: two case reports and analysis of 11 additional reported cases. Semin Arthritis Rheum 2002;31:338-45
   Google Scholar
• Zeuner RA, Schroeder JO, Schroder F, Euler HH. Successful application of high dose intravenous immunoglobulins in Sjogren's syndrome associated arthritis. Ann Rheum Dis 1995;54:936
   PubMedGoogle Scholar
• Pisoni CN, Brucato A, Ruffatti A, Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010;62:1147-52
   PubMed Web of Science ®Google Scholar
• Friedman DM, Llanos C, Izmirly PM, Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010;62:1138-46
   PubMed Web of Science ®Google Scholar
• Yamashita H, Takahashi Y, Kaneko H, Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjogren's syndrome: two cases and a literature review. Mod Rheumatol 2012; [Epub ahead of print]
   Google Scholar
• Simon JA, Lazo-Langner A, Duarte-Rojo A, Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjogren's syndrome. J Clin Apher 2002;17:44-6
   Google Scholar
• Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93
   PubMed Web of Science ®Google Scholar
• Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998;18:255-62
   PubMed Web of Science ®Google Scholar
• Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:38-44
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Demols P, Salmon I, Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6
   PubMed Web of Science ®Google Scholar
• Zandbelt MM, de Wilde P, van Damme P, Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:1389-96
   PubMedGoogle Scholar
• Ramos-Casals M, Sanz I, Bosch X, B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012;125:327-36
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Tant L, Burmester GR, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label phase I/II study. Arthritis Res Ther 2006;8(4):R129
   PubMed Web of Science ®Google Scholar
• Meijer J, Meiners P, Vissink A, Effective rituximab treatment in primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM, Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Pennec Y, Morvan J, Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310-17
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK, Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50
   PubMed Web of Science ®Google Scholar
• Seror R, Sordet C, Guillevin L, Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2007;66:351-7
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O, Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
   PubMed Web of Science ®Google Scholar
• Mekinian A, Ravaud P, Hatron PY, Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012;71:84-7
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, BIOGEAS Study Group. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76
   PubMed Web of Science ®Google Scholar
• Vasil'ev VI, Logvinenko OA, Kokosadze NV, First experience with the application of rituximab for the treatment of patients with Sjogren's syndrome and disease. Vestn Ross Akad Med Nauk 2009;2:3-10
   Google Scholar
• Pollard RP, Pijpe J, Bootsma H, Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study. J Rheumatol 2011;38:2198-208
   PubMed Web of Science ®Google Scholar
• Mekinian A, Ravaud P, Larroche C, Club Rhumatismes et Inflammation. Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: results from the AIR registry. Clin Exp Rheumatol 2012;30:208-12
   PubMed Web of Science ®Google Scholar
• Mekinian A, Ravaud P, Hatron PY, Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012;71:84-7
   PubMed Web of Science ®Google Scholar
• Voulgarelis M, Ziakas PD, Papageorgiou A, Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore) 2012;91:1-9
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Tolerance and efficacy of rituximab in primary Sjogren syndrome: final results of a randomized controlled trial. Arthritis Rheum 2012;64(Suppl):S1079
   Google Scholar
• Toumeh A, Josh N, Narwal R, Assaly R. Refractory thrombotic thrombocytopenic purpura associated with primary sjogren syndrome treated with rituximab: a case report. Am J Ther 2012; [Epub ahead of print]
   Google Scholar
• Zhou L, Xin XF, Wu HX. The efficacy and safety of low-dose rituximab in treatment of primary Sjogren's syndrome with thrombocytopenia. Zhonghua Nei Ke Za Zhi 2012;51:37-41
   Google Scholar
• Uraoka Y, Tanigawa T, Watanabe K, Complete remission of protein-losing gastroenteropathy associated with Sjogren's syndrome by B cell-targeted therapy with rituximab. Am J Gastroenterol 2012;107:1266-8
   PubMed Web of Science ®Google Scholar
• Swartz MA, Vivino FB. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjogren's syndrome with rituximab. J Clin Rheumatol 2011;17:454
   Google Scholar
• Rueda JC, Duarte-Rey C, Casas N. Successful treatment of relapsing autoinmune pancreatitis in primary Sjogren's syndrome with rituximab: report of a case and review of the literature. Rheumatol Int 2009;29:1481-5
   PubMedGoogle Scholar
• Sanchez-Cano D, Callejas-Rubio JL, Lara-Jimenez MA, Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008;17:228-9
   PubMed Web of Science ®Google Scholar
• Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea 2007;26:886-7
   Google Scholar
• Seve P, Gachon E, Petiot P, Successful treatment with rituximab in a patient with mental nerve neuropathy in primary Sjogren's syndrome. Rheumatol Int 2007;28:175-7
   Google Scholar
• Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren's syndrome with rituximab. Scand J Rheumatol 2006;35:323-5
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Nolle B, Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis 2005;64:1087-8
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman S, EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren's syndrome. Ann Rheum Dis 2010;62:551-8
   Google Scholar
• Seror R, Ravaud P, Mariette X, EULAR Sjogren's Task Force. EULAR Sjogren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72
   PubMed Web of Science ®Google Scholar
• Meiners PM, Arends S, Brouwer E, Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302
   PubMed Web of Science ®Google Scholar
• Engel P, Gomez-Puerta JA, Ramos-Casals M, Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56
   PubMed Web of Science ®Google Scholar
• Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066-73
   PubMed Web of Science ®Google Scholar
• Brkic Z, Maria NI, van Helden-Meeuwsen CG, Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2012; [Epub ahead of print]
   Google Scholar
• Youinou P, Saraux A, Pers JO. B-lymphocytes govern the pathogenesis of Sjogren's syndrome. Curr Pharm Biotechnol 2012;13:2071-7
   Google Scholar
• Mariette X, Gottenberg JE. Pathogenesis of Sjogren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Fabris M, BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2012; [Epub ahead of print]
   Google Scholar
• Ramos-Casals M. The B-lymphocyte stimulator connection in Sjogren's syndrome. Rheumatology (Oxford) 2012; Epub ahead of print
   Google Scholar
• Mariette X, Quartuccio L, Seror R, Results of the BELISS study, the first open phase 2 study of belimumab in primary Sjogren syndrome. Arthritis Rheum 2012;64(Suppl):S1079-80
   Google Scholar
• Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:326-37
   PubMed Web of Science ®Google Scholar
• Chen YT, Lazarev S, Bahrami AF, Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjogren's syndrome. Lab Invest 2012;92:556-70
   PubMed Web of Science ®Google Scholar
• Chen YT, Nikulina K, Lazarev S, Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome. Am J Pathol 2010;177:1333-43
   PubMed Web of Science ®Google Scholar
• Norheim KB, Harboe E, Gøransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome–a double blind, randomised clinical trial. PLoS ONE 2012;7:e30123
   PubMed Web of Science ®Google Scholar